Most healthcare providers recommend waiting until after breastfeeding ends to start semaglutide, unless maternal health risks justify treatment under close medical supervision
While microdosing programs are not intended for significant weight loss, program participants may experience reduced appetite and cravings, leading to gradual, sustained weight management
In the latest studies, both Retatrutide & Pemvidutide proved to have the potential to aid with cardiometabolic improvements, such as blood pressure, cholesterol, fasting glucose, glycated hemoglobin, & triglycerides
Human data are somewhat more reassuring for accidental early exposure, but there is still not enough evidence to recommend continuing these medications throughout pregnancy